We don’t follow footsteps.
We create the path.

News & events

“Cellacon Valley”
Read about Spark Therapeutics’ contributions to what Philadelphia Magazine is calling “Cellacon Valley”

Read More read more

Q1 2017 earnings
Spark Therapeutics reports Q1 2017 financial results and recent business progress

Read More read more

ARVO 2017
Spark Therapeutics will present several posters at the upcoming ARVO Annual Meeting

Read More read more

ID YOUR IRD
Genetic testing now available to eligible patients with certain IRDs through the new Spark initiative, ID YOUR IRD

Read More read more

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More